You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
SciBase Q2’24: Forward - but positive cash flow still in the distance
Important partnerships established in the USA, first order received from Austria. Cash burn is still high. Analyst Antti Luiro summarizes.
00:00 Intro
00:14 Q2 summary
01:41 Partnership with Unified Health
03:01 First order from Austria
04:28 Cash position
06:42 No news on insurance reimbursement
07:12 Valuation & recommendation
Read our latest report: Still waiting for more signals of accelerating growth
Herantis Pharma as an Investment | Life Science Night Dec. 2, 2024
Aiforia as an Investment | Life Science Night Dec. 2, 2024
Faron Pharmaceuticals as an Investment | Life Science Night Dec. 2, 2024
Life Science Companies as Investments | Life Science Night Dec. 2, 2024
Life Science Night | December 2, 2024
View all videos